Skip to Content
Søk Menu

Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers

DESTINY-Brest03 was a prospective randomized phase 3 clinical trial that aimed to compare the efficacy of trastuzumab deruxtecan (T-DXd) with that of trastuzumab emtansine (T-DM1) in patients suffering from HER2 positive metastatic breast cancers.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Towards a Stronger and Unified Nordic Region in Breast Cancer Research and Treatment

/ BestPractice Nordic
BröstcancerNBCN

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24
Sara Hurvitz

Use of Anthracyclines Should Be Re-Evaluated for Treatment of Breast Cancer

/ Sara A. Hurvitz
BröstcancerOnkologisk Forum 2024 Play the Video 03:12

Another Step Forward for Breast Cancer Treatment

/ BestPractice Nordic
BröstcancerESMO24
Hope Rugo

Abemaciclib Shows Significant Benefit for HR-positive HER2-negative Patients with Advanced Breast Cancer

/ Hope S. Rugo
Bröstcancer Play the Video 11:57

Nordic Collaboration on Breast Cancer Research Reignited

/ BestPractice Nordic
Bröstcancer
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
BröstcancerESMO24 Play the Video 04:50
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
BröstcancerESMO24 Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
BröstcancerESMO24 Play the Video 1:23
Back to top